EMD Millipore, the Life Science division of Merck KGaA of Germany, has launched the CellPrime recombinant human lysozyme for increased recovery efficiencies in biopharmaceutical production. Especially suited for lysing Micrococcus and E. coli, it delivers a five-fold increase in target protein recovery as compared with animal-derived lysozyme, the version commonly used in production. The increased efficiency offered by CellPrime recombinant human lysozyme, combined with high activity levels, results in a reduction of overall production costs when compared with animal-derived lysozyme.
While proteins are typically expressed in E. coli at high levels, extraction of functional protein is a critical step in the bioproduction process. Successful recovery is dependent on effective extraction methods such as disruption of bacterial cells by lysozyme or other enzymatic means.
Use of animal-derived lysozyme for extracting protein therapeutics has significant drawbacks, including high lot-to-lot variation. In contrast, CellPrime recombinant human lysozyme is a more active cell lysis reagent, from non-animal origin, and is more consistent by virtue of being recombinant. As a result, it delivers increased protein yield while reducing regulatory concerns around animal-derived raw materials and risk of adventitious agents.
